Orexigen Therapeutics - Comparative Multiple Analysis

Orexigen Therapeutics (Comparative Multiple Analysis)

placeholder_large_analysis.png
Banner%20-%20The%20perfect%20tool%20for%20investors%281%29.gif

Notes on the Comparative Multiple Analysis of Orexigen Therapeutics

WikiWealth compares Orexigen Therapeutics's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Orexigen Therapeutics's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Orexigen Therapeutics.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Orexigen Therapeutics's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Orexigen Therapeutics's Analysis


How does this work? The Comparative Investment Analysis determines the value of Orexigen Therapeutics by comparing Orexigen Therapeutics financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Orexigen Therapeutics.

See the Orexigen Therapeutics cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Orexigen Therapeutics.

Also, see the Orexigen Therapeutics's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Orexigen Therapeutics's valuation conclusion for a quick summary.